Wellington Management Group LLP Lowers Position in Savara Inc (NASDAQ:SVRA)

Wellington Management Group LLP lessened its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 36.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,481,654 shares of the company's stock after selling 3,142,358 shares during the period. Wellington Management Group LLP owned approximately 3.19% of Savara worth $16,829,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Frazier Life Sciences Management L.P. raised its holdings in shares of Savara by 6.2% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 8,660,379 shares of the company's stock worth $26,587,000 after purchasing an additional 502,994 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock worth $482,000 after purchasing an additional 31,168 shares during the period. Woodline Partners LP raised its holdings in shares of Savara by 16.6% in the 4th quarter. Woodline Partners LP now owns 2,686,938 shares of the company's stock worth $8,249,000 after purchasing an additional 381,743 shares during the period. Vestal Point Capital LP raised its holdings in shares of Savara by 33.2% in the 4th quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company's stock worth $33,079,000 after purchasing an additional 2,685,000 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in shares of Savara by 178.1% in the 4th quarter. Squarepoint Ops LLC now owns 122,635 shares of the company's stock worth $376,000 after purchasing an additional 78,540 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Stock Performance

SVRA stock traded down $0.11 during midday trading on Thursday, reaching $2.38. 962,314 shares of the company's stock traded hands, compared to its average volume of 1,426,384. The firm has a market capitalization of $411.35 million, a PE ratio of -5.53 and a beta of 0.44. Savara Inc has a 52 week low of $1.89 and a 52 week high of $5.11. The company has a 50-day moving average price of $2.89 and a two-hundred day moving average price of $2.93. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). As a group, equities analysts anticipate that Savara Inc will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on SVRA shares. HC Wainwright cut shares of Savara from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $6.00 to $2.00 in a report on Thursday, May 29th. Evercore ISI lowered their target price on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Wells Fargo & Company lowered their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Finally, Guggenheim reissued a "buy" rating and set a $8.00 target price (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.